Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with cervical cancer at stage IIb to IVa, where the cancer type is squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma
- People who have completed a full course of combined chemotherapy and radiation therapy (chemoradiation), using specific radiation doses and a platinum-based chemotherapy drug (cisplatin or carboplatin)
- People whose MRI scan, taken within 4 weeks of finishing chemoradiation, shows remaining tumour (a main tumour area of at least 10mm, or a lymph node of at least 15mm in shortest width)
- People with a good general activity level, able to carry out daily activities with little or no restriction (confirm with trial site)
- People whose doctors expect them to live longer than six months
- People whose blood test results meet minimum levels for red blood cells, white blood cells, and platelets (confirm specific values with trial site)
- People whose liver and kidney function blood tests are within an acceptable range (confirm specific values with trial site)
- Women who could become pregnant must have a negative pregnancy test within 7 days before joining, and must agree to use contraception throughout the trial
Who may not be able to join:
- People with an active or uncontrolled serious infection
- People with liver cirrhosis or advanced liver disease that is no longer compensated
- People with a history of immune system deficiency, including HIV-positive status or a congenital (present from birth) immune deficiency condition
- People whose kidneys are not working well enough to tolerate chemotherapy
- People who have had, or currently have, another type of cancer
- People with a history of heart attack, serious irregular heartbeat, or moderate-to-severe heart failure
- People who have previously had targeted therapy or a procedure to block the pelvic arteries
- People who have had a blood clot in an artery or vein within the past 6 months
- People with an autoimmune disease
- People who need to take medications that may cause liver or kidney damage
- People whose cancer continued to grow or spread during chemoradiation treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dongling Zou, M.D., Chongqing University Cancer Hospital
Phone: 13657690699
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
PFS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.